Novo Holdings A/S Reports Dilution of Ownership in Edgewise Therapeutics to 4.9%

On April 27, 2026, Novo Holdings A/S filed an amendment to its Schedule 13D regarding its investment in Edgewise Therapeutics, Inc. (EWTX). The filing reports that as of April 23, 2026, Novo Holdings A/S ceased to be a beneficial owner of more than five percent of the Issuer's common stock. Specifically, the reporting person holds 5,350,000 shares, which now represents approximately 4.98% of the outstanding common stock (rounded to 4.9% for filing purposes). This decrease in ownership percentage was not caused by a sale of securities, but rather by the dilution of the reporting person's position following an increase in the Issuer's total outstanding shares. As of April 9, 2026, the Issuer reported 107,532,173 shares outstanding. Novo Holdings A/S, which is wholly owned by the Novo Nordisk Foundation, maintains sole voting and dispositive power over these shares. No transactions in the Issuer's common stock were effected by the reporting person within the sixty days prior to this filing.